Toll Free: 1-888-928-9744
Published: Apr, 2014 | Pages:
53 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Alexion Pharmaceuticals, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Alexion Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Alexion Pharmaceuticals, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Alexion Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Alexion Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Alexion Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Alexion Pharmaceuticals, Inc.'s pipeline products Reasons to buy - Evaluate Alexion Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Alexion Pharmaceuticals, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Alexion Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Alexion Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Alexion Pharmaceuticals, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Alexion Pharmaceuticals, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Alexion Pharmaceuticals, Inc. Snapshot 5 Alexion Pharmaceuticals, Inc. Overview 5 Key Information 5 Key Facts 5 Alexion Pharmaceuticals, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Alexion Pharmaceuticals, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Alexion Pharmaceuticals, Inc. - Pipeline Products Glance 11 Alexion Pharmaceuticals, Inc. - Late Stage Pipeline Products 11 Phase III Products/Combination Treatment Modalities 11 Alexion Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 12 Phase II Products/Combination Treatment Modalities 12 Phase I Products/Combination Treatment Modalities 13 Alexion Pharmaceuticals, Inc. - Early Stage Pipeline Products 14 Preclinical Products/Combination Treatment Modalities 14 Alexion Pharmaceuticals, Inc. - Drug Profiles 15 eculizumab 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 asfotase alfa 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 ALXN-1101 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 ALXN-1007 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 ALXN-1102 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 ALXN-1103 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Monoclonal Antibody For Undisclosed Indication 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Alexion Pharmaceuticals, Inc. - Pipeline Analysis 24 Alexion Pharmaceuticals, Inc. - Pipeline Products by Target 24 Alexion Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 25 Alexion Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 26 Alexion Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 27 Alexion Pharmaceuticals, Inc. - Recent Pipeline Updates 28 Alexion Pharmaceuticals, Inc. - Dormant Projects 36 Alexion Pharmaceuticals, Inc. - Discontinued Pipeline Products 37 Discontinued Pipeline Product Profiles 37 pexelizumab 37 Alexion Pharmaceuticals, Inc. - Company Statement 38 Alexion Pharmaceuticals, Inc. - Locations And Subsidiaries 48 Head Office 48 Other Locations & Subsidiaries 48 Appendix 52 Methodology 52 Coverage 52 Secondary Research 52 Primary Research 52 Expert Panel Validation 52 Contact Us 53 Disclaimer 53
List of Tables Alexion Pharmaceuticals, Inc., Key Information 5 Alexion Pharmaceuticals, Inc., Key Facts 5 Alexion Pharmaceuticals, Inc. - Pipeline by Indication, 2014 8 Alexion Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 9 Alexion Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 10 Alexion Pharmaceuticals, Inc. - Phase III, 2014 11 Alexion Pharmaceuticals, Inc. - Phase II, 2014 12 Alexion Pharmaceuticals, Inc. - Phase I, 2014 13 Alexion Pharmaceuticals, Inc. - Preclinical, 2014 14 Alexion Pharmaceuticals, Inc. - Pipeline by Target, 2014 24 Alexion Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 25 Alexion Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 26 Alexion Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 27 Alexion Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 28 Alexion Pharmaceuticals, Inc. - Dormant Developmental Projects,2014 36 Alexion Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2014 37 Alexion Pharmaceuticals, Inc., Other Locations 48 Alexion Pharmaceuticals, Inc., Subsidiaries 49
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.